Literature DB >> 19672639

Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2.

Eiji Ito1, Kiyoshi Saito, Hiroshi Yatsuya, Tetsuya Nagatani, Goro Otsuka.   

Abstract

We retrospectively reviewed characteristics of patients with neurofibromatosis type 2 to identify factors predicting further growth of bilateral vestibular schwannomas. Subjects comprised 27 neurofibromatosis type 2 patients with 54 vestibular schwannomas, followed for 24-204 months (mean, 86 months). This study investigated factors predictive of vestibular schwannoma growth in neurofibromatosis type 2. Features distinguishing actively growing from quiescent VS were determined for untreated course (28 vestibular schwannomas) and posttreatment course (including either resection or radiosurgery; 33 vestibular schwannomas). A general estimation equation was used to identify factors affecting tumor growth. During the untreated course, 19 vestibular schwannomas showed growth and 9 vestibular schwannomas were stable. No factors predictive of growth were shown. During the posttreatment course (23 surgical resections, ten radiosurgeries), ten treatments were followed by growth and 23 were followed by stability, with growth showing an association with onset at an early age (p = 0.007). Multivariate analysis identified no factors predictive of growth. After treatment, close follow-up is warranted for patients with onset at an early age.

Entities:  

Mesh:

Year:  2009        PMID: 19672639     DOI: 10.1007/s10143-009-0223-3

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  23 in total

1.  A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; D Teare; V Newton; T Strachan; R Ramsden; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

Review 2.  National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. The Consensus Development Panel.

Authors: 
Journal:  Arch Neurol       Date:  1994-02

3.  The neuroimaging and clinical spectrum of neurofibromatosis 2.

Authors:  V F Mautner; M Lindenau; M E Baser; W Hazim; M Tatagiba; W Haase; M Samii; R Wais; S M Pulst
Journal:  Neurosurgery       Date:  1996-05       Impact factor: 4.654

4.  Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2.

Authors:  M Samii; C Matthies; M Tatagiba
Journal:  Neurosurgery       Date:  1997-04       Impact factor: 4.654

5.  Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease.

Authors:  M H Ruttledge; A A Andermann; C M Phelan; J O Claudio; F Y Han; N Chretien; S Rangaratnam; M MacCollin; P Short; D Parry; V Michels; V M Riccardi; R Weksberg; K Kitamura; J M Bradburn; B D Hall; P Propping; G A Rouleau
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

6.  Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study.

Authors:  Victor-Felix Mautner; Michael E Baser; Sarang D Thakkar; Urs M Feigen; J M Friedman; Lan Kluwe
Journal:  J Neurosurg       Date:  2002-02       Impact factor: 5.115

7.  Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.

Authors:  Michael E Baser; Erini V Makariou; Dilys M Parry
Journal:  J Neurosurg       Date:  2002-02       Impact factor: 5.115

8.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

9.  Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases.

Authors:  R A Sobel
Journal:  J Neuropathol Exp Neurol       Date:  1993-03       Impact factor: 3.685

10.  Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases.

Authors:  J Jääskeläinen; A Paetau; I Pyykkö; G Blomstedt; T Palva; H Troupp
Journal:  J Neurosurg       Date:  1994-03       Impact factor: 5.115

View more
  6 in total

1.  Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.

Authors:  Michael S Dirks; John A Butman; H Jeffrey Kim; Tianxia Wu; Keaton Morgan; Anne P Tran; Russell R Lonser; Ashok R Asthagiri
Journal:  J Neurosurg       Date:  2012-04-13       Impact factor: 5.115

2.  Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2.

Authors:  Matthieu Peyre; Stephane Goutagny; Sandrine Imbeaud; Alexis Bozorg-Grayeli; Michele Felce; Olivier Sterkers; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2011-07-28       Impact factor: 12.300

3.  Clinical outcome of neurofibromatosis type 2-related vestibular schwannoma: treatment strategies and challenges.

Authors:  Byung Sup Kim; Ho Jun Seol; Jung-Il Lee; Hyung Jin Shin; Kwan Park; Doo-Sik Kong; Do-Hyun Nam; Yang-Sun Cho
Journal:  Neurosurg Rev       Date:  2016-05-04       Impact factor: 3.042

4.  Retrosigmoid Versus Translabyrinthine Approach for Acoustic Neuroma Resection: An Assessment of Complications and Payments in a Longitudinal Administrative Database.

Authors:  Tyler Cole; Anand Veeravagu; Michael Zhang; Tej Azad; Christian Swinney; Gordon H Li; John K Ratliff; Steven L Giannotta
Journal:  Cureus       Date:  2015-10-30

5.  The impact of stereotactic radiosurgery in the management of neurofibromatosis type 2-related vestibular schwannomas.

Authors:  Leonardo Lustgarten
Journal:  Surg Neurol Int       Date:  2013-04-17

6.  Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality.

Authors:  Isabel Gugel; Julian Zipfel; Philip Hartjen; Lan Kluwe; Marcos Tatagiba; Victor-Felix Mautner; Martin Ulrich Schuhmann
Journal:  Childs Nerv Syst       Date:  2020-06-16       Impact factor: 1.475

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.